Abstract 466P
Background
Brain stem tumors are among the most severe oncological diseases in children. The only real method of help remains radiation therapy, which makes it possible to alleviate the severity of neurological disorders, but for most patients, the effect achieved, regardless of the type of ionizing radiation used, is temporary and after various periods (from 3 months to several years), the tumor resumes growth. The main purpose of our work was to determine the possibilities and prospects of repeated radiation therapy in children with diffuse brain stem tumors.
Methods
In the period 1998-2022, analysis of short and long-term results of 132 children and adolescents with brainstem tumors treated at the Russian Scientific Center of Roentgenoradiology were evaluated. Out of 132 patients treated at RNCRR, 60 children were selected whose remission lasted more than 9 months and the Lansky scale of more than 40 points for re-irradiation.
Results
As a result of re-irradiation, out of 45 children with a Lansky status of 40-50 points, it was improved in 36 (80%). An additional 15 children were included in the group with an initial Lansky status of 70-90 points, initially represented by one child, and only 9 patients' condition worsened or did not change. The median life expectancy in the group of patients after one course of radiation therapy was 13.9 months, but in the group of those treated repeatedly - 22.6 months.
Conclusions
Re-irradiation using 30.0 to 45.0 Gy in standard fractionation in combination with adequate accompanying therapy in 90% of cases allows an increase in the remission period in dense tumors and temporarily improve the quality of life in cystic solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
596P - Dose-individualisation of fluoropyrimidines in <italic>DPYD</italic> wild-type patients: Final results from the Alpe2U study
Presenter: Niels Heersche
Session: Poster session 16
597P - Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Presenter: Filipa Simões
Session: Poster session 16
598TiP - PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Presenter: Thomas Aparicio
Session: Poster session 16
599TiP - PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Presenter: Tomoki Sakakida
Session: Poster session 16
600TiP - A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Presenter: Maria Elena Elez Fernandez
Session: Poster session 16
601TiP - A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Presenter: Ilya Pokataev
Session: Poster session 16
602TiP - Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Presenter: Jun Huang
Session: Poster session 16
454P - Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Presenter: Juan Manuel Sepúlveda
Session: Poster session 16
455P - Phase II trial of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer
Presenter: Yatian Liu
Session: Poster session 16
456P - Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Presenter: Manuel Alejandro Mazariegos-Rubi
Session: Poster session 16